Substance / Medication

Ruxolitinib

Overview

Active Ingredient
ruxolitinib
RxNorm CUI
1193326
Labeler: Incyte CorporationUpdated: 2025-06-24T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Ruxolitinib cream improves outcomes in atopic dermatitis: An updated systematic review and meta-analysis.
Ghanem Laura, Mendoza-Millán Daniela Lucía, Lopes Bárbara Baptista et al. · Pediatr Allergy Immunol · 2026
PMID: 41556257Meta-Analysis
Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives.
Spadafora Marco, Morsia Serena, Di Lernia Vito Giuseppe et al. · Exp Dermatol · 2025
PMID: 40192197Meta-AnalysisFull text (PMC)
Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: A systematic review and meta-analysis of randomized controlled trials.
Ehsan Muhammad, Rehman Aqeeb Ur, Ayyan Muhammad et al. · J Cosmet Dermatol · 2024
PMID: 38161317Meta-Analysis
Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
Baccelli Francesco, Gottardi Francesca, Muratore Edoardo et al. · Bone Marrow Transplant · 2024
PMID: 38402346Meta-AnalysisFull text (PMC)
A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
Grossmann Meghan C, Haidari Wasim, Feldman Steven R · J Drugs Dermatol · 2023
PMID: 37410047Meta-Analysis
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.
Appeldoorn T Y J, Munnink T H Oude, Morsink L M et al. · Clin Pharmacokinet · 2023
PMID: 37000342Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ruxolitinib (substance)
SNOMED CT
702806008
UMLS CUI
C2931926
RxNorm CUI
1193326
Labeler
Incyte Corporation

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.